ArticleCell metabolism2018
Metformin: An Old Dog with a New Trick?
Article in Cell metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness and mechanism of metformin in animal models of pulmonary fibrosis: A preclinical systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Metformin alleviates cholestasis-associated nephropathy through regulating oxidative stress and mitochondrial function.Liver research (Beijing, China) · 2021Article
- Transient phases of OXPHOS inhibitor resistance reveal underlying metabolic heterogeneity in single cells.Cell metabolism · 2021Article
- Macrophage metabolic reprogramming during chronic lung disease.Mucosal immunology · 2021Review
- ENERGY SENSING PATHWAYS IN AGING AND CHRONIC LUNG DISEASE.Transactions of the American Clinical and Climatological Association · 2020Article
- Role of Metabolism in Hepatic Stellate Cell Activation and Fibrogenesis.Frontiers in cell and developmental biology · 2018Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) remains an important medical challenge, but recent translational data have provided clues implicating deficient AMPK signaling in persistently activated myelofibroblasts within fibrotic foci. A new study in Nature Medicine reports that pharmacological activation of AMPK with metformin can reverse established fibrosis by facilitating deactivation and apoptosis of myofibroblasts.
Indexed as
Identifiers
30184483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.